# OnCo record pancreatic-adenosquamous-carcinoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/pancreatic-adenosquamous-carcinoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "pancreatic-adenosquamous-carcinoma" ;
  schema:name "Adenosquamous carcinoma of the pancreas"@en ;
  schema:alternateName "Adenosquamous carcinoma of the pancreas (squamous component of at least 30 percent; about 1 percent of cases; body and tail; worse after resection)"@en, "Pancreatic adenosquamous carcinoma"@en, "ASCP"@en, "Adenosquamous pancreatic cancer"@en, "Mixed adenocarcinoma and squamous cell carcinoma of the pancreas"@en ;
  schema:description "Adenosquamous carcinoma is a rare form of pancreatic cancer in which at least three tenths of the tumour has turned into squamous cells, the flat cells of skin-like linings. It is found more often in the body and tail, tends to be larger and poorly differentiated, and does worse after surgery than ordinary pancreatic cancer, though surgery remains the strongest predictor of survival."@en ;
  schema:url <https://onco.cc/cancers/pancreatic-adenosquamous-carcinoma/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Adenosquamous_carcinoma> ;
  schema:citation <https://doi.org/10.1111/his.13975>, <https://doi.org/10.1016/j.jss.2011.06.015>, <https://doi.org/10.1002/jso.25112>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455> ;
  onco:tag "gi", "pancreatic", "subtype-page" ;
  onco:related <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/pancreatic-colloid-carcinoma/>, <https://onco.cc/cancers/pancreatic-undifferentiated-carcinoma-ogc/>, <https://onco.cc/cancers/gallbladder-adenosquamous-squamous-carcinoma/>, <https://onco.cc/cancers/lung-adenosquamous-carcinoma/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/histopathology-ihc/> ;
  onco:targets <https://onco.cc/targets/kras/>, <https://onco.cc/targets/tp53/> ;
  onco:drugs <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/drugs/nalirifox/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pancreatic-cancer-signalling/> ;
  onco:terms <https://onco.cc/terms/tumour-grade/>, <https://onco.cc/terms/whipple/>, <https://onco.cc/terms/distal-pancreatectomy/>, <https://onco.cc/terms/resection-margins/> ;
  onco:standardOfCare <https://onco.cc/terms/whipple/>, <https://onco.cc/terms/distal-pancreatectomy/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/drugs/nalirifox/> .